Naproxen and cromolyn as new glycogen synthase kinase 3β inhibitors for amelioration of diabetes and obesity: An investigation by docking simulation and subsequent in vitro/in vivo biochemical evaluation

Animals; Binding Sites; Cromolyn Sodium; Diabetes Mellitus; Glycogen Synthase Kinase 3; Humans; Mice; Molecular Docking Simulation; Naproxen; Obesity; Protein Binding; Protein Conformation; Animalia; Mus; adiponectin; C peptide; cromoglycate disodium; glucose; glycogen; glycogen synthase kinase 3 inhibitor; glycogen synthase kinase 3beta; insulin; naproxen; resistin; cromoglycate disodium; glycogen synthase kinase 3; glycogen synthase kinase 3 beta; naproxen; protein binding; article; body weight; drug protein binding; enzyme inhibition; enzyme linked immunosorbent assay; glucose blood level; glycogen analysis; in vitro study; in vivo study; insulin blood level; molecular docking; non insulin dependent diabetes mellitus; obesity; protein blood level; weight reduction; animal; antagonists and inhibitors; binding site; chemistry; diabetes mellitus; enzymology; human; mouse; obesity; protein conformation